Amarin Hit Hard On Summer Street Commentary, Acquisition Possible After Omthera Buyout [View article]
I sold all my QCOR last week to jump on AMRN and NOK, I strongly believe AMRN is one of the best value play this year, MARINE approval brought the stock to 15.8, I don't see anything below 18 for ANCHOR approval. And for the point if ANCHOR will be approved, I think it's a joke not to believe in the needs as well as the efficiency and safety profile of the drug!
Amarin - The Yo-Yo Of M&A Speculators [View article]
I forgot to mention as well, BASF has exclusive deal to provide API to AMRN. So with this acquisition, I guess Lovaza no longer exists since BASF can't sell API to any other than AMRN
From AMRN's 10K:
Our goal in expanding our supply chain is to provide greater capacity to meet anticipated demand, enable supply diversification and flexibility and introduce cost competition. After conducting an extensive global search for manufacturers capable of producing Vascepa API to our technical specifications, in 2011 we entered into limited exclusivity, long-term agreements with two additional API suppliers, Chemport and BASF (formerly Equateq Limited). In each case, following FDA qualification of the supplier for the manufacture of API for commercial sale and other milestones relating to manufacturing capacity, these agreements include annual purchase levels to enable Amarin to maintain exclusivity with each respective supplier, and to prevent potential termination of the agreements. We recently agreed to terms with a fourth API supplier, which terms are subject to contingencies that we anticipate will be satisfied in 2012. Certain of our API supply agreements contain provisions under which the cost of supply to us decreases as we purchase increased product volume.
Amarin - The Yo-Yo Of M&A Speculators [View article]
Good news today,
BASF bought Pronova which is the supplier of Lovaza.
The interesting thing is the price they bought it was cheap (24% premium for average price in the last 6 months). GSK could have bought Pronova with slightly more premium so it can lower the production cost of Lovaza, but it did not do so.
That brought me to thinking GSK was reserving cash for something bigger, and better than Lovaza.....
Amarin's Chart And Background Are Indicating A Jump On The Horizon [View article]
I remember like 2 weeks ago it got the patent then the stock went up to 12.25 before went down to 10.25 because of market melt-down, was that not the case?
Amarin Hit Hard On Summer Street Commentary, Acquisition Possible After Omthera Buyout [View article]
Amarin - The Yo-Yo Of M&A Speculators [View article]
From AMRN's 10K:
Our goal in expanding our supply chain is to provide greater capacity to meet anticipated demand, enable supply diversification and flexibility and introduce cost competition. After conducting an extensive global search for manufacturers capable of producing Vascepa API to our technical specifications, in 2011 we entered into limited exclusivity, long-term agreements with two additional API suppliers, Chemport and BASF (formerly Equateq Limited). In each case, following FDA qualification of the supplier for the manufacture of API for commercial sale and other milestones relating to manufacturing capacity, these agreements include annual purchase levels to enable Amarin to maintain exclusivity with each respective supplier, and to prevent potential termination of the agreements. We recently agreed to terms with a fourth API supplier, which terms are subject to contingencies that we anticipate will be satisfied in 2012. Certain of our API supply agreements contain provisions under which the cost of supply to us decreases as we purchase increased product volume.
Read more: http://bit.ly/10cmlKP
Amarin - The Yo-Yo Of M&A Speculators [View article]
BASF bought Pronova which is the supplier of Lovaza.
The interesting thing is the price they bought it was cheap (24% premium for average price in the last 6 months). GSK could have bought Pronova with slightly more premium so it can lower the production cost of Lovaza, but it did not do so.
That brought me to thinking GSK was reserving cash for something bigger, and better than Lovaza.....
Staying long and strong!
If AMR101 Is Approved, Sell Amarin [View article]
Amarin's Chart And Background Are Indicating A Jump On The Horizon [View article]